Home > Insider Trading > Filing (0001179110-14-009751)

Filing Details

Accession Number:: 0001179110-14-009751
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-06-04 17:02:38
Reporting Period:: 2014-06-02

Filing Date:: 2014-06-04
Accepted Time:: 2014-06-04 17:02:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1280600	Acceleron Pharma Inc	XLRN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1586752	D Steven Ertel	128 Sidney Street Cambridge MA 02139	Svp & Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-06-02	7,500	$5.08	35,156	No	4	M	Direct
Common Stock	Disposition	2014-06-02	7,300	$29.71	27,856	No	4	S	Direct
Common Stock	Disposition	2014-06-02	200	$30.04	27,656	No	4	S	Direct
Common Stock	Acquisiton	2014-06-02	2,500	$0.40	30,156	No	4	M	Direct
Common Stock	Acquisiton	2014-06-02	2,500	$29.73	27,656	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2014-06-02	7,500	$0.00	48,750	$5.08
Common Stock	Option to Purchase Common Stock	Disposition	2014-06-02	2,500	$0.00	11,875	$0.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,250		2018-03-27	No	4	M	Direct
9,375		2016-01-18	No	4	M	Direct

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.02 to $30.01, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any securityholder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.04, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any securityholder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.17 to $30.06, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any securityholder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.